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One of the major goals of cancer treatment is to develop therapies
affecting cancer cells while causing little or no damage to the
normal counterparts. In this perspective numerous attempts have
been made to bind anti-tumour compounds or radioactive isotopes
to molecules specifically taken up by tumour cells. One example
of these molecules is benzylguanidine, a structural analogue of
noradrenaline, which is selectively taken up by cells of neural crest
origin including tumours such as pheochromocytoma and neuro-
blastoma (Jaques et al, 1987; Montaldo et al, 1991). Linking
radioactive iodine to benzylguanidine has led to the synthesis of
123I- and 131I-metaiodobenzylguanidine (*I-MIBG), which at low
doses have become an important tool for both diagnosis and
follow-up of these tumours (Buck et al, 1985; Geatti et al, 1985).
Moreover, given at higher doses 131I-MIBG has proven to be active
against these tumours, especially neuroblastoma (Schwabe et al,
1987; Klingebiel et al, 1989). Most clinical studies have been
carried out on patients in advanced stages of the neoplasia (Italian
MIBG Workshop, 1987; Klingebiel et al, 1989; Lashford et al,
1992), although recently 131I-MIBG has been administered to poor-
risk patients as up-front therapy in an attempt to improve their
outcome (Mastrangelo et al, 1993, 1998; Weber et al, 1996).
Despite all this information the precise role of 131I-MIBG in the
overall therapeutic strategy of neuroblastoma is far from being
defined. In particular, it is still unclear whether 131I-MIBG might
improve the tumour response of patients who did not achieve
complete remission with conventional therapy and are therefore
predisposed to disease progression and death. Since 1986 it has
been the policy of our institute to use 131I-MIBG as therapy for
stage 3 and 4 neuroblastoma patients with MIBG-positive residual
disease after front-line protocol. We have thus accumulated
considerable experience in this area.
The results of this experience are hereby reported. They suggest
that  131I-MIBG may provide additional therapeutic benefits for
some of these patients, although related toxicity may occasionally
be severe.
MATERIALS AND METHODS
Patients
Patients were registered in this study between March 1986 and
December 1996. They were diagnosed with inoperable or dissemi-
nated neuroblastoma (INSS stage 3 and stage 4 respectively)
(Brodeur et al, 1993) in ages ranging from 1 to 15 years. Diagnosis
of neuroblastoma and evaluation of disease extent was carried out
according to standard clinical and pathologic criteria of the Italian
Cooperative Group for Neuroblastoma (ICGNB) (De Bernardi
et al, 1992). Treatment was given according to ICGNB protocols
(De Bernardi et al, 1992). In order to be eligible for this study
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patients had to have either (a) stage 3 disease with residual tumour
positive at the 123I- or 131I-MIBG scintigraphy at end of first-line
therapy (group A), or (b) stage 4 disease partially responsive to
first-line therapy with residual tumour at the level of primary
tumour and/or skeleton (no more than four lesions) and/or bone
marrow (only if infiltration was of minimal entity) with at least
one lesion clearly uptaking 123I- or 131I-MIBG (group B). The
cohort of 43 patients in this study (13 stage 3 and 30 stage 4) repre-
sents all the patients with these characteristics treated in our insti-
tution. This accounts for approximately one-third of the patients
enrolled in the Italian protocols between 1985 and 1996 who
reached partial response to first-line therapy (28 out of 76 stage 3
and 102 out of 281 stage 4 patients). In the same period we diag-
nosed and treated 36 stage 3 and 112 stage 4 patients aged more
than 1 year.
Further eligibility criteria included recovery of haematopoiesis
from previous chemotherapy, and normal renal, hepatic and
thyroid functions. Parents or guardian were informed of the exper-
imental nature of this treatment and requested to give written
consent. The study was approved by the Ethical Committee of the
Giannina Gaslini Children’s Hospital.
Evaluation before 131I-MIBG therapy
Pretreatment evaluation included physical examination, complete
blood cell count with platelet and differential white cell count,
blood tests showing normal thyroid, kidney and liver functions,
imaging studies of the primary tumour with computerized tomog-
raphy and/or magnetic resonance imaging and 123I- or 131I-MIBG
scintigraphy, measurement of tumour markers (vanillylmandelic
[VMA] and homovanillic [HVA] acids in urine; ferritin, neuron-
specific enolase and lactate dehydrogenase in serum) and marrow
evaluation consisting of four aspirations and two trephine biop-
sies.
Disease evaluation to assess tumour response was performed
between 3 and 6 weeks after each 131I-MIBG course.
Evaluation of tumour response
Tumour response was defined as follows (Brodeur et al, 1993):
complete response (CR), disappearance of primary tumour and of
all metastatic lesions with normalization of urine catecholamines;
very good partial response (VGPR), > 90% volume reduction of
the primary tumour with clearing of all measurable metastatic
lesions with the exception of residual changes at skeletal scintig-
raphy, normalization of urine catecholamines; partial response
(PR), > 50% volume reduction of the primary tumour and of all
measurable metastatic lesions, residual marrow infiltration in only
one site; mixed response (MR), > 50% reduction of any measur-
able lesion (primary or metastases) with < 50% reduction in any
other and < 25% increase in any existing lesion; no response (NR),
< 50% reduction but < 25% increase in any existing lesion;
progressive disease (PD), increase > 25% of any measurable
lesion or appearance of a new lesion(s).
The isolated decrease of 131I-MIBG uptake was not considered
evidence of tumour response. Response was evaluated 4–8 weeks
following each 131I-MIBG course. The best response achieved is
reported in the Results section of the article and in the Tables.
Some patients underwent further improvement several months
after completion of 131I-MIBG therapy and the best status achieved
is reported in the outcome.
131I-MIBG therapy
The administered doses of 131I-MIBG ranged from 2.5 to 5.5 GBq
according to body weight: 2.5–3.7 GBq for patients weighing less
than 15 kg; 3.7–4.7 GBq for patients weighing 15–20 kg; 5.5 GBq
for those weighing more than 20 kg. Specific activity ranged from
1.1 to 2.8 GBq mg–1 (median 1.6). Doses were determined
attempting to give at least 2000 cGy to the tumour and possibly
less then 200 cGy to the whole body (Beirewaltes, 1987).
Thyroid gland uptake of radioiodine was blocked by oral
administration of iodine (2–3 mg kg–1 day–1 of iodine as Lugol’s
solution) given for 5 days before and 8 days after 131I-MIBG
Table 1 Stage 3 patients (group A)
Case Sex, Primary NMYC Time (months) Tumour lesion at 131I-MIBG therapy 131I-MIBG Tumour Clinical course
no. age tumour copies from therapy response and outcome
(yrs) site diagnosis courses after
to 131I-MIBG Primary VMA–HVA 131I-MIBG
therapy tumour urinary therapy
1 F, 2 Thorax 1 7 Yes E 2 NR Alive 131 months, SD
2 M, 3 Thorax 1 6 Yes E 4 PR Alive 107 months, CR
3 F, 2 RPG 1 5 Yes E 3 NR Alive 98 months, SD
4 M, 12 Adrenal 1 14 Yes E 2 NR Alive 89 months, SD
5 F, 1 RPG ND 1 Yes E 4 NR Alive 78 months, CR
6 F, 2 RPG 32 7 Yes E 3 PR Alive 79 months, CR
7 M, 3 RPG 1 7 Yes E 4 NR Alive 77 months, SD
8 F, 3 Thorax 1 8 Yes E 3 NR Alive 71 months, SD
9 M, 1 RPG 1 5 Yes E 4 MR Alive 56 months, SD
10 F, 1 Adrenal 1 5 Yes E 4 NR Alive 56 months, SD
11 F, 4 RPG 14 8 Yes E 3 PD Dead 17 months, PD
12 M, 2 Adrenal 1 6 Yes E 1 NR Alive 47 months, CR
13 M, 1 RPG 1 8 Yes E 2 NR Alive 34 months, SD
RPG, retroperitoneal ganglia; B, bone; (s), single lesion; (m), multiple lesions; BM, bone marrow; LN, distant lymph node; CR, complete remission; PR, partial
remission; MR, minor response; NR, no response; SD, stable disease; PD, progressive disease; N normal, E elevated, ND, not done. aAcute myeloid leukaemia
presently in remission. bAcute myeloid leukaemia under treatment.infusion. During hospitalization patients were kept in single
rooms. Close relatives actively participated in nursing care and
were provided with film dosimetry. Once discharged patients were
checked weekly for haematological indices and at longer intervals
for other organic functions.
Toxic effects attributable to 131I-MIBG therapy were evaluated
according to WHO criteria (WHO, 1979). The duration of 131I-
MIBG treatment depended on tumour response and toxicity. In
case of either disease improvement or stability after the first 131I-
MIBG course, additional courses up to a maximum of 5 with an
interval of 4–6 weeks between courses were administered unless
evidence of progressive disease was documented or excessive
myelotoxicity had occurred.
RESULTS
Group A consisted of 13 stage 3 disease patients who had had
partial tumour response to first-line regimen. Before 131I-MIBG
therapy 11 patients underwent second-look surgery consisting of
partial tumour resection in four and of a biopsy only in seven with
histological evidence of viable tumour cells in all surgical speci-
mens. At the time of entry into this study all patients but one had
abnormal urinary catecholamine excretion. All showed patholog-
ical scintigraphic *I-MIBG uptake at the site of the primary.
Main patients’ data including characteristics at diagnosis,
interval from diagnosis to 131I-MIBG therapy, number of courses
of  131I-MIBG administered, tumour response to 131I-MIBG and
outcome are listed in Table 1. In all but one patient NMYC gene
1380 A Garaventa et al
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Figure 1 EFS in stage 3 and four patients who received I131-MIBG therapy
for residual neuroblastoma
Table 2 Stage 4 patients (group B)
Case Sex, Primary NMYC Time (months) from Tumour lesions at131 I-MIBG therapy 131I-MIBG Tumour Clinical course
no. age tumour copies diagnosis therapy response and outcome
(years) site to 131I-MIBG courses after
therapy Primary Metastases VMA–HVA 131I-MIBG
tumour urinary therapy
1 F, 3 RPG ND 25 Yes No E 4 PR Alive 153 months, CRa
2 M, 4 RPG 1 10 Yes No N 2 NR Dead 21 months, PD
3 M, 2 Adrenal ND 11 Yes No E 3 NR Death 22 months, PD
4 M, 2 RPG 32 7 Yes No N 3 PR Alive 67 months, CR
5 F, 1 Adrenal 9 7 Yes No N 1 PR Alive 65 months, CR
6 F, 17 RPG 1 21 Yes No E 2 NR Alive 57 months, SD
7 F, 3 RPG 1 13 Yes No N 2 PR Alive 47 months, SD
8 M, 1 RPG 1 12 Yes No N 2 NR Alive 36 months, SD
9 F, 2 Adrenal 1 9 Yes No E 2 NR Dead 21 months, PD
10 M, 14 RPG 1 18 Yes No N 2 NR Alive 30 months, SD
11 F, 2 RPG 1 5 Yes O(m), MO N 3 NR Dead 10 months, PD
12 M, 3 Adrenal 20 6 Yes O(m), MO E 5 NR Dead 14 months, PD
13 M, 4 Adrenal ND 16 Yes O(m) E 1 PD Dead 19 months, PD
14 M, 2 Adrenal ND 9 Yes LN E 2 PD Dead 12 months, PD
15 M, 6 RPG ND 14 Yes MO E 2 NR Dead 20 months, PD
16 F, 1 RPG ND 13 Yes O(m), MO E 3 PR Dead 19 months, PD
17 F, 4 RPG 1 11 Yes O(m), MO E 3 PR Alive 39 months, SDb
18 M, 4 RPG 1 12 Yes LN E 3 NR Dead 20 months, PD
19 M, 16 RPG 1 12 Yes LN E 2 NR Alive 48 months, SD
20 M, 11 RPG 14 9 Yes O(m) N 2 NR Dead 13 months, PD
21 M, 1 RPG 3 10 Yes LN N 3 NR Toxic death, 13 months
22 M, 2 RPG 20 10 Yes MO E 3 PR Dead 14 months, PD
23 M, 4 Adrenal 1 12 Yes B(m), BM N 3 PR Dead 16 months, PD
24 M, 5 Adrenal 1 17 Yes B(m), BM N 1 PD Dead 24 months, PD
25 F, 4 Adrenal ND 14 Yes B(m), BM E 2 NR Alive 24 months, PD
26 M, 4 RPG 1 10 Yes B(s), BM N 1 NR Alive 22 months, SD
27 M, 2 Adrenal 1 8 No BM N 4 PD Dead 9 months, PD
28 F, 1 Adrenal 1 12 No B(s) E 3 PR Alive 60 months, CR
29 F, 3 Adrenal 1 17 No B(m) N 1 CR Alive 68 months, CR
30 M, 2 Adrenal 3 21 No BM E 2 PR Alive 45 months, PD
RPG, retroperitoneal ganglia; B, bone; (s), single lesion; (m), multiple lesions; BM, bone marrow; LN, distant lymph node; CR, complete remission; PR, partial
remission; MR, minor response; NR, no response; SD, stable disease; PD, progressive disease; N normal, E elevated, ND, not done. aAcute myeloid leukaemia
presently in remission. bAcute myeloid leukaemia under treatment.was studied, and in two patients an abnormal copy number was
present.
One patient received one 131I-MIBG course, three patients
received two courses, four received three courses and five received
four courses. The interval between courses ranged from 4 to 8
weeks (median, 7). Two patients had partial and one had mixed
response (< 25% reduction of tumour volume with return to
normal of catecholamines). The disease remained stable in nine
patients and progressed in one alone.
No further antitumour therapy was administered and four
patients became progressively disease-free including normal *I-
MIBG scan despite some ‘irregularity’ detected by imaging
studies at level of primary tumour and interpreted as possible scar
tissue. They are now alive at 47–107 months (median, 78) from
diagnosis (case nos 2, 5, 6, 12). Eight patients are alive with stable
disease (residual tumour persisting at imaging and MIBG scan) at
24–131 months (median, 74). Four of them underwent biopsy of
the residual tumour with histological findings of ganglioneuroma
in two (case nos 3, 7) and of ganglioneuroblastoma in the other
two (case nos 4, 9). The only case (no. 11) who developed PD after
131I-MIBG therapy died 9 months later. He was one of the two
patients with an amplified NMYC gene. The 5-year event-free
survival (EFS) of this group is 92% (± 0.07) with follow-up of
34–131 months (median, 78) (Figure 1).
Group B consisted of 30 patients with stage 4 disease who
achieved partial response with first-line therapy. Twenty-one
received  131I-MIBG therapy within 2 months from completion of
their chemotherapy protocol ending in a course of myeloablative
therapy, while in the remaining nine patients 131I-MIBG therapy
was not preceded by myeloablative therapy due to (a) inoperable
primary tumour (five patients), (b) bone marrow infiltration by
tumour preventing autologous stem cell harvest (two patients),
and (c) lack of adequate harvest (two patients). Scintigraphy
performed before 131I-MIBG therapy was positive at one site in 11
patients (at level of primary in ten, a unique bone lesion in one),
two sites in five, three or more sites in 14.
Main patient data are summarized in Table 2. Five patients
received one 131I-MIBG course of therapy, 13 received two
courses, nine received three courses, two received four courses and
one received five courses. Intervals between courses ranged from
4 to 16 weeks (median, 7).
One patient (case no. 29) achieved CR (clearing of two bone
lesions) and is presently alive disease-free 50 months later. Eleven
patients had PR involving the primary tumour (the only tumour
lesion) in four cases (nos 1, 4, 5, 7), a single bone lesion in one
case (case no. 28), bone marrow in one (case no. 30), bone marrow
plus primary in one (case no. 22), and bone plus bone marrow and
primary in three (case nos 16, 17, 23). Eight of them are alive at
36–153 months (median, 53) among whom four are  in CR (case
nos 1, 4, 5, 28) including case no. 1 who developed myeloid
leukaemia and is presently in CR after allogeneic bone marrow
graft, two cases who had no further disease change (case nos 8, 17)
including case no. 17 who developed myeloid leukaemia and is
still alive after 14 months and one (case no. 30) who is alive with
PD. Fourteen patients did not respond. Among them one is alive
with PD at 24 months (case no. 25) and five are alive with stable
disease (case nos 6, 8, 10, 19, 26) at 22–88 months (median, 42)
from diagnosis, while the remaining nine patients died, among
whom seven of disease at 13–21 months (median, 20) and two of
toxicity.
The last four patients (case nos 13, 14, 24, 27) experienced early
PD and died within a few months. The 5-year EFS of this group is
40% (± 0.08) (Figure 1).
Patients having a single tumour lesion positive at *I-MIBG scan
had better chance of survival with eight out of 11 surviving, four of
whom in CR. Of the four patients with two positive lesions, two
are presently alive with non-progressive disease and one is alive in
CR. Of the 14 with three or more *I-MIBG-positive lesions, only
three are currently alive among whom two with stable disease and
one with PD.
Bone marrow infiltration at time of 131I-MIBG therapy was
prognostically unfavourable, since only three of 11 such patients
are presently alive, one with stable disease and two with PD.
Of the 18 patients with normal NMYC copy number, 11 are
alive; out of four patients with amplified NMYC only one
survives, and two out of seven patients not evaluated for this gene
survive.
The majority of patients who responded to 131I-MIBG therapy
and survive are those who received 131I-MIBG after myeloablative
therapy. In fact, out of 21 such patients nine responded (one CR,
eight PR), nine had no disease change (one died of toxicity and
eight progressed) and three developed progressive disease. On the
contrary, in the group of nine patients who were not eligible for
such a therapy only one responded, although a total of four are
alive with stable disease.
Toxicity
Acute toxicity
No noticeable reaction was registered during or shortly after the
administration of 131I-MIBG courses.
Haematological toxicity (Table 3)
Among the group A patients the main toxicity of this type attribut-
able to 131I-MIBG was thrombocytopenia. However, out of 32
evaluable courses only two patients had grade 4 thrombocytopenia
and three others had grade 3 toxicity which did not worsen with
subsequent courses. Six patients, for a total of 24 courses, mani-
fested no haematological toxicity.
In group B patients 58/72 courses were evaluable. Only one
patient had no marrow toxicity. Grade 4 thrombocytopenia
occurred after 19 course* grade 3 leukopenia occurred after
18 courses. None of the 21 patients who received therapeutic
131I-MIBG after myeloablative chemotherapy and autologous stem
cell rescue had grade 4 haematological toxicity, although 12
developed grade 3 and seven grade 2 thrombocytopenia, which
was often long-lasting (2–7 months; median 5).
131I-MIBG therapy for residual neuroblastoma 1381
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Table 3 Haematological toxicity after 131I-MIBG therapy
Course I II III >IV Total
Stage 3: evaluable course 12 11 7 2 32
Leukopenia:             grade 3 – 1 – – 1
4– – – – –
Thrombocytopenia:  grade 3 – 3 – – 3
4– 1 1 – 2
Stage 4: evaluable courses 25 21 9 3 58
Leukopenia:             grade 3 2 5 1 – 8
4– – – – –
Thrombocytopenia:  grade 3 9 3 1 – 13
48 7 3 1 1 91382 A Garaventa et al
British Journal of Cancer (1999) 81(8), 1378–1384 © 1999 Cancer Research Campaign
Both thrombocytopenia and leukopenia occurred in most cases
3–5 weeks following administration of 131I-MIBG therapy.
Lymphocytopenia below 1 ´ 109 L–1 was found only after nine of
50 evaluable courses and appeared earlier (7–10 days after
131I-MIBG infusion) than other haematological toxicities.
Other toxicities
One stage 4 disease patient (case no. 21) treated with megatherapy
and autologous bone marrow rescue, followed by three courses of
131I-MIBG therapy, developed interstitial pneumopathy 1 month
after the last course and died. One stage 4 patient (case no. 17)
developed acute myeloid leukaemia (FAB M2) 1 year after the last
(third) 131I-MIBG course. She had previously received carboplatin
for a total dose of 4.4 g m–2, cyclophosphamide for 14.4 g m–2,
etoposide for 1.5 mg m–2 and melphalan for 140 mg m–2, plus
27 Gy radiation therapy to the primary tumour site. Another stage
4 disease patient (case no. 1) who had received 1.8 g m–2 of pepti-
chemio, 600 mg m–2 of cisplatin and only one course of 131I-MIBG,
developed myeloid leukaemia 6 years later, which was success-
fully treated by an unrelated marrow graft. This patient is presently
alive disease-free 12 years after the initial diagnosis.
Twenty-one patients showed compensated hypothyroidism
(high thyroid-stimulating hormone plasma level with normal T3
and T4 values). Thyroid abnormalities appeared between 1 and
44 months (median, 12) after the first dose of 131I-MIBG.
Subsequently, 15 patients developed overt hypothyroidism
requiring replacement treatment with L-thyroxine at 2–56 months
(median, 19) after initiation of 131I-MIBG therapy. Thyroid func-
tion remained normal in 19 patients having at least 1 year of
follow-up (17–98 months, median, 45).
DISCUSSION
Long-term survival of children with inoperable or disseminated
neuroblastoma diagnosed after the age of 1 year remains largely
unsatisfactory mainly because current treatment commonly fails to
eradicate the disease (Garaventa et al, 1993; Haase et al, 1995;
Philip et al, 1997). Thus, until innovative and more effective ther-
apies are developed the paediatric oncologist dealing with refrac-
tory or partially responsive neuroblastoma must struggle to
optimize the therapeutic tools at his disposal (Castleberry et al,
1991; Gaze et al, 1995; Leavey et al, 1997).
When radioiodinated benzylguanidine became available for the
diagnosis of neural crest-derived tumours the possibility to use it at
much higher doses for therapeutic purposes brought about a great
deal of interest. Both 125I- and 131I-labelled MIBG seemed suitable
due to their different physical characteristics. The former emits
short-range energy making it theoretically suitable to destroy small
tumour aggregates (Buck et al, 1985), while the long-range radia-
tion emitted of 131I could be more effective to induce damage of
larger tumour lesions (Weber et al, 1996). However, since residual
neuroblastoma is usually not homogeneous, 125I short-range
radioactivity might miss part of the tumour and was consequently
abandoned with few exceptions (Sisson et al, 1996) and the thera-
peutic use of radioactive MIBG has been limited to 131I-MIBG.
Initial phase I–II studies with 131I-MIBG therapy, dating back to
the late 1980s, showed good tolerance and demonstrated objective
tumour responses in 20–60% of patients failing to respond to
modern therapies (Italian MIBG Workshop, 1987; Schwabe et al,
1987; Klingebiel et al, 1989; Lashford et al, 1992). In addition,
significant pain relief was noticed even in patients who did not
exhibit objective responses (Klingebiel et al, 1989). Since the
anti-tumour effect is dose-dependent with a maximum tolerated
dose of 12 mCi kg–1, autologous stem cell rescue has been used to
allow dose escalation up to 18 mCi kg–1 (Matthay et al, 1998).
Lastly, attempts are being made to evaluate whether 131I-MIBG
given as front-line therapy may improve the outcome of these
patients without causing excessive toxicity (Van Hasselt et al,
1996; Mastrangelo et al, 1998). No prospective study has been
carried out so far to the true potential value of MIBG therapy and
to identify the group of patients who may profit best from this
treatment modality. The difficulties in design such studies include
the rarity of neuroblastoma, the fact that many centres do not
possess the facilities to deliver the treatment to young patients, the
high cost of the drug and, not least, the psychological burden of
keeping patient in a radiation protected environment with limited
parental contact extended for several days.
In a previous study we reported on 31 patients treated after
relapse or progression: the rate and degree of responses were lower
in the presence of bulky disease, a high number of MIBG-positive
lesions, long duration of previous therapy and overt bone marrow
infiltration (Garaventa et al, 1991).
In the present study we administered 131I-MIBG as therapy to
children with high-risk neuroblastoma who responded to first-line
therapy without achieving CR, provided that the residual primary
tumour and/or metastase(s) were clearly uptaking MIBG. Our
objective was to increase knowledge on toxicity of repeated cycles
and the possibly to improve the outcome of these children. Our
results indicate that stage 3 disease patients did benefit from this
treatment. Despite the fact that only two out of 13 of them had a
greater than 50% decrease of the residual primary tumour at short-
term evaluation after completion of 131I-MIBG therapy, two others
later experienced a progressive decrease in tumour size until its
disappearance without receiving further anti-tumour therapy. The
disease has remained stable for a median of 75 months in eight
other patients. Four of these eight patients eventually underwent
biopsy of the residual tumour, which turned out to be ganglio-
neuroma in two cases and ganglioneuroblastoma, with marked
evidence of differentiation in the other two. The disease
progressed in only one patient after 131I-MIBG therapy. It is of
interest that this patient had abnormal MYCN gene copy number,
although a similar patient is a long survivor. Presently, 12 out of 13
patients are alive either disease-free or with stable disease with an
observation period of several years in most cases (Figure 1).
Since several authors have reported that incomplete tumour
excision in stage 3 disease is associated with a worse survival rate
(Garaventa et al, 1993; Haase et al, 1995; Powis et al, 1996), we
believe that our results should be considered worthy of interest
despite the fact that only one of our long-term survivors had ampli-
fication of MYCN gene.
The possible benefit of 131I-MIBG therapy for stage 4 disease
patients is more difficult to prove in this study. Among 30 such
patients only one achieved a CR and survives. However, ten other
patients experienced a PR and six of them are alive. No tumour
change was seen in 15 patients, six of whom are alive despite the
absence of additional treatment. Four patients developed early
progression and died. Tumour response and outcome correlated
with the extent of the disease at the time of 131I-MIBG therapy. In
fact, of 11 patients with a single positive lesion at 123I-MIBG
scintigraphy eight survive with stable disease, while of 19 with
two or more positive lesions only five survive. This last group
includes 12 patients with bone marrow involvement of whom only
two survive without tumour progression.131I-MIBG therapy for residual neuroblastoma 1383
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Twenty-one of the 30 stage 4 disease patients received thera-
peutic 131I-MIBG within 3 months from myeloablative therapy.
Although we expected severe and long-lasting haematological
toxicity in these patients, they tolerated the radioiodinated treat-
ment surprisingly well. In particular no severe haemorrhagic
episodes were recorded, though three patients required several
platelet transfusions.
However, important non-haematological toxicity which was not
encountered in stage 3 disease, did occur in stage 4, possibly due
to the overall greater amount of chemotherapy usually given to
these patients as well as occasional irradiation to large proportions
of the bone marrow and skeleton. One example was the early
occurrence of fatal interstitial pneumonia that one patient devel-
oped within 2 months after the last 131I-MIBG therapy course. The
precocity of this complication suggests that the elevated concen-
tration of the radioactive compound in the pulmonary bloodstream
during  131I-MIBG therapy may aggravate a pre-existing immune
deficiency favouring the growth of opportunistic micro-organ-
isms. This hypothesis is confirmed by the increased risk of
pneumopathy reported in lymphoma patients treated with
131I-charged monoclonal antibodies (Press et al, 1995). According
to these authors, after bone marrow, the organs which are most
likely to develop toxicity from radioiodinated therapy are the
lungs. This should therefore be taken into consideration when
planning doses and duration of this type of treatment. Even more
concern raises the early occurrence of leukaemia in two out of
30 stage 4 disease patients since it could represent the result of a
combined chemo-radiotherapeutic effect on bone marrow
precursor cells. A similar case has recently been reported in a
series of 30 children enrolled in a therapeutic 131I-MIBG dose-
finding study (Matthay et al, 1998). If the risk of secondary
leukaemia in neuroblastoma patients subjected to 131I-MIBG
therapy proved true, then the limits of this treatment would have to
be more clearly defined. Subclinical hypothyroidism was frequent
in our series. Statistical analysis to determine the role of factors
such as age, numbers and doses of 131I-MIBG courses could not be
performed due to the small number of cases. Compliance to
thyroid blockade is a critical point, however, although greater
attention will be paid to minimize this complication in the future
and a close follow-up of thyroid status is necessary. Few patients
required chronic substitutive therapy and no significant impact on
the quality of life was reported.
In conclusion, our data suggest that 131I-MIBG therapy may
provide additional anti-tumour effects in stage 3 neuroblastoma
with residual disease after first-line therapy and this may translate
into an overall improved outcome. This favourable result has been
reached with the only side-effects being tolerable haematological
and thyroid toxicity. In our opinion, the fact that 12 out of 13 such
patients are alive could justify a prospective study of 131I-MIBG
therapy in this particular subset of patients. 131I-MIBG exhibited
antitumour activity in approximately one-third of stage 4 patients.
Interestingly enough, the haematological toxicity of this treatment
was of moderate entity even for patients who had previously
received myeloablative therapy. Overall, our results suggest that
the addition of 131I-MIBG at therapeutic dosages to the conven-
tional regimens for high-risk neuroblastoma may implement
tumour response in some patients and this might translate in better
chance of cure for some of them. Controlled clinical trials should
be considered to define the true potential of this new therapeutic
tool. However, since trials aiming to respond such an important
question would imply the long lasting commitment of highly
specialized centres and a potential severe toxicity the cost– benefit
ratio of such a study deserves to be carefully eveluated.
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